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Abrin (ABR), a protein puriﬁed from the seeds of Abrus precatorius, induces apoptosis in various types of cancer cells. However,
the detailed mechanism remains largely uncharacterized. By using a cDNA microarray platform, we determined that prohibitin
(PHB), a tumor suppressor protein, is signiﬁcantly upregulated in ABR-triggered apoptosis. ABR-induced upregulation of PHB
is mediated by the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway, as demonstrated by chemical
inhibitors.Inaddition,ABRsigniﬁcantlyinducedtheexpressionofBaxaswellastheactivationofcaspase-3andpoly(ADP-ribose)
polymerase (PARP) in Jurkat T cells, whereas the reduction of PHB by speciﬁc RNA interference delayed ABR-triggered apoptosis
throughtheproapoptoticgenesexamined.Moreover,ourresultsalsoindicatedthatnucleartranslocationofthePHB-p53complex
may play a role in the transcription of Bax. Collectively, our data show that PHB plays a role in ABR-induced apoptosis, which may
be helpful for the development of diagnostic or therapeutic agents.
1.Introduction
Abrin (ABR), puriﬁed from the seeds of Abrus precatorius,
belongs to the family of type II ribosome-inactivating
proteins (RIPs) that contain 2 subunits. These include a toxic
A chain with RNA N-glycosidase activity and a galactose-
binding B chain with lectin activity [1]. Like ricin from
Ricinus communis, the A chain of ABR functions via the
inhibition of protein biosynthesis through depurination
of a single adenine residue (A4324) of the 28S ribosomal
RNA [2, 3]. In contrast, the B chain of ABR functions by
interacting with the galactose moiety of glycoproteins or
glycolipids on the cell membrane and is internalized into
cells through receptor-mediated endocytosis. Several reports
have documented that ABR is mitogenic [4], antifertility
[5], antitumoral [6, 7], and immunopotentiating [8–12]
agent. In addition to its ability to inhibit protein synthesis,
ABR is believed to adopt alternative mechanisms to trigger
cell apoptosis [13]; despite this, it is relatively less toxic to
normal cells than to cancer cells [10, 14]. Our previous
studies have implied that apoptosis induced by ABR could
be partially independent of its RNA N-glycosidase activity
and instead be mediated by its binding and the decrease of
antioxidant protein-1 (AOP-1), increase of reactive oxygen
species production, and release of cytochrome c into the
cytosol [15].
Prohibitin (PHB) is localized on the cell membrane,
mitochondria, and nucleus; this localization may play a
pivotal role in its regulation of cell-cycle progression by the
inhibition of DNA replication in multiple cell types [16].
The protumorigenic versus antitumorigenic role of PHB in
cancer cells remains controversial. An oncogenic role has
been identiﬁed for PHB in diﬀerent kinds of cancer cells,
including those of the breast [17], bladder [18], gastric
[19], ovary [20], and prostate [21], whereas PHB’s role as
a tumor suppressor has been demonstrated in esophageal
squamous cell carcinoma [22–26]. These opposing eﬀects
of PHB in cancer may be due to 2 possible mechanisms.
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subcellular localization; increased levels of PHB on the cell
membrane facilitates tumorigenesis through its interaction
with c-Raf induced by the Ras oncogene [28], whereas
increased levels of PHB in the nucleus induces apoptosis
by increasing the transcriptional activity of p53 and its
translocation to the cytoplasm [29].
In order to understand the genetic basis of the apoptotic
signaling exerted by ABR, a microarray platform was used
to investigate the expression proﬁles of genes in Jurkat T
cells after ABR exposure. Among the genes identiﬁed, PHB
was signiﬁcantly upregulated; however, it has yet to be deter-
mined whether PHB plays a role in ABR-triggered apoptosis.
Here, we report that overexpression of PHB is involved in
ABR-triggered Jurkat T cell apoptosis. Upregulation of PHB
through the JNK/SAPK pathway activated the pro-apoptotic
gene Bax via the accumulation and translocation of the
PHB-p53 complex to the cytoplasm. The elucidation of the
changes in gene expression and the cellular mechanisms
of the response to ABR exposure may be helpful for the
development of diagnostic or therapeutic agents.
2.MaterialsandMethods
2.1. Isolation of ABR. ABR was isolated from seeds of the
red variety of A. precatorius using Sepharose 6B aﬃnity
column chromatography and puriﬁed as described in a
previousstudy[30].ThepurityandmolecularweightofABR
protein were conﬁrmed by Coomassie blue staining (data
not shown). The stock protein solution was diluted with
phosphate-buﬀered saline (PBS, pH 7.2) to a concentration
of 100μM.
2.2. Cells and Culture Conditions. The human Jurkat T
leukemia cancer cell line was obtained from American Type
Culture Collection and maintained in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine serum,
100U/mL penicillin, and 100μg/mL streptomycin. Cells
were grown in suspension in a 5% CO2 humidiﬁed atmo-
sphere at 37◦C.
2.3. Cell Proliferation Assay. Cells were seeded in 96-well
plates at a density of 5 × 103 cells per well and were treated
with (various doses) or without ABR. At the indicated times,
viable cells were analyzed by measuring the conversion of the
tetrazolium salt 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-
5-tetrazolio]-1,3-benzene disulfonate (WST-1) to formazan.
The formazan dye produced by metabolically active cells
was measured with a scanning multiwell spectrophotometer
after 4h of incubation, according to the manufacturer’s
instructions.
2.4. The cDNA Microarray System. The gene expression
patterns regulated by ABR were analyzed with a previously
established cDNA microarray platform (9600 probes) [31].
The mRNA from cells with or without ABR treatment
was extracted using an Oligotex-dT column (Qiagen). A
2mg quantity of each mRNA sample was labeled with
biotin or digoxigenin for membrane hybridization, dual-
color detection, and image analysis as described previously
[31].
2.5. Antibodies and Chemical Inhibitors. Anantibody speciﬁc
to PHB was purchased from Lab Vision Corporation.
An antibody speciﬁc to p53 was obtained from Santa
Cruz Biotechnology. Antibodies speciﬁc to cleaved-caspase-
3, and cleaved-poly(ADP-ribose) polymerase (PARP) were
purchased from Cell Signaling. Antibodies against Bax and
actinwereobtainedfromChemicon.Thechemicalinhibitors
PD 98059, SB 203580, and SP600125 were purchased from
Sigma.
2.6. Immunoblotting. T o t a lc e l ll y s a t e sw e r ec o l l e c t e di nl y s i s
buﬀer (50mM HEPES-KOH, pH 7.5, 1% Triton X-100,
150mM NaCl, and protease inhibitor cocktail (Roche)).
The extracts were centrifuged at 14000rpm for 20min, and
then the clear supernatant was separated by using 10%
SDS-PAGE. After transferred, the separated proteins to a
polyvinyldene ﬂuoride (PVDF) membrane (Immunobilon-
P, 0.45mm; Millipore, Billerica, Mass, USA) by using the
NA-1512 semi-dry transfer apparatus (NIHON EIDO), the
membranes were blocked with 5% skim milk in trisbuﬀered
saline containing 1% Tween 20 (TBST, pH 7.4) at room
temperature for 30min and then incubated overnight at
4◦C with primary antibodies. The membranes were washed
4 times with TBST for 10min each at room temperature
and incubated with HRP-conjugated secondary antibodies
for 1h at room temperature. The membranes were then
washed 4 times with TBST. The proteins were visualized
using the SuperSignal West Femto Chemiluminescent Kit
(Thermo Scientiﬁc) and exposed to an X-ray ﬁlm (Kodak).
The Image J program (http://rsb.info.nih.gov/)w a su s e df o r
quantization the expression fold. For western blot analysis,
the fold increase of the indicated proteins was determined
by normalizing to corresponding actin expression. For IP-
westernanalysis,thedensitometryreadingsofthebandswere
normalized to control.
2.7. Enzyme-Linked Immunosorbent Assay (ELISA) for Phos-
phor MAPK Detection. Cells were treated with or without
ABR after pretreating with the indicated inhibitors or vehicle
(DMSO) alone. After the indicated period of time, cells were
harvested and lysed as above. The PathScan MAP Kinase
Multi-Target Sandwich ELISA kit was used to determine
phosphor ERK, -p38, and-JNK/SAPK levels according to
manufacturer’s instruction (Cell Signaling).
2.8.ShortInterferingRNA. ShortinterferingRNAs(siRNAs)
against PHB (sc-37629) and the negative control siRNA
(sc-37007) were obtained from Santa Cruz Biotechnology.
At o t a lo f2× 105 cells were plated in a 6-well plate
for 24h, and siRNA transfection was carried out using
the Lipofectamine 2000kit according to the manufacturer’s
instructions (Invitrogen).Evidence-Based Complementary and Alternative Medicine 3
2.9. Terminal Deoxynucleotidyl Transferase-Catalyzed Deox-
yuridine Triphosphate (dUTP)-Nick End Labeling (TUNEL)
Method [15]. A p o p t o t i cc e l ld e a t hw a se x a m i n e db yT U N E L
method as manufactory’s suggestion (Roche Molecular Bio-
chemicals). Each sample with 1 × 104 events was analyzed
with a Becton-Dickinson FACSCalibur, and the distribution
of cells was determined.
2.10. Chromatin Immunoprecipitation (ChIP) Assays. Cells
treated with or without ABR for the indicated time periods
were examined. After ﬁxing the protein-DNA complex using
formaldehyde (1% ﬁnal concentration) at room temperature
for 10min, the reaction was stopped with glycine. After
washed and lysed the cells, the lysates were sonicated and
centrifuged, and the supernatants were used for immuno-
precipitation of Bax with PHB antibody or control IgG.
Antibody-bound protein/DNA complexes were precipitated
and eluted in 300μLo fe l u t i o nb u ﬀer (1% SDS, 50mM
NaHCO3). Cross-linking was reversed by heating at 65◦C
for 4h. The DNA was resuspended in 200μL of distilled
water and treated with 30μg of proteinase K at 37◦Cf o r
1h, followed by phenol/chloroform extraction and ethanol
precipitation. PCR was conducted using 100ng of DNA as
the template. The following PCR primers were used for
the Bax promoter: forward primer 5 -CCGGGAATTCCA-
GACTGCA-3  and reverse primer 5 -AGCTCTCCCCAG-
CGCAGAA-3 . Each band was quantitatively determined
using the Image J program (http://rsb.info.nih.gov/). The
densitometry readings of the bands were normalized to the
input.
2.11. Statistical Analysis. SPSS 12.0 for Windows (SPSS
Inc.) was used to analyze the data. A two-tailed paired-
samples Student’s t-test was used for statistical analysis of the
comparative data from the two groups. P-value <0.05 values
were considered statistically signiﬁcant.
3. Results
3.1. ABR Induces Upregulation of PHB in Human Jurkat T
Cells. To evaluate the eﬀect of ABR on leukemia cells in
vitro, Jurkat T leukemia cells were exposed to 0.01–100nM
of ABR for 24h. The cell viability was then determined by
WST-1 assay. As shown in Figure 1(a), the growth of Jurkat
TcellswasreducedbyABRinadose-dependentmanner.The
value of the 50% cytotoxic concentration (CC50) for the 24h
treatment was determined for the water fraction to be 0.32
± 0.06nM. The data are represented as mean ± SD from 3
independent experiments.
Microarray analysis was used to identify novel candidates
that are diﬀerentially expressed after 1nM ABR treatment
for 3h. A total of 128 genes, out of the 9600 probes tested,
were signiﬁcantly altered by >1.5-fold in response to ABR
(P<0.05). The top 10 signiﬁcant up-/down-regulated genes
are listed in Table 1, sorted by fold increase or decrease.
PHB, a signiﬁcantly upregulated gene with diverse cellular
functions, was selected for further investigation. To explore
the potential role of PHB in ABR-treated apoptosis, Jurkat
T cells were ﬁrst treated with ABR (0.1–10nM). As shown
in Figure 1(b), ABR signiﬁcantly increased the expression
of PHB protein after treatment for 9h. Cells were further
treated with 1nM ABR for diﬀerent time periods. An initial
increase of PHB protein was observed at the 3h time point
and was sustained for up to 18h after ABR treatment
(Figure 1(c)). To determine whether PHB upregulation due
to ABR is because of increased transcription or increased
RNA stability, the RNA synthesis inhibitor actinomycin
D or the protein synthesis inhibitor cyclohexamide was
preincubated with cells for 1h before ABR was added.
The results show that not only actinomycin D but also
cyclohexamide signiﬁcantly diminished ABR-induced PHB
upregulation (Figure 1(d)). This ﬁnding suggests that ABR-
induced PHB upregulation requires de novo RNA synthesis.
3.2. ABR Upregulates PHB Expression through the SAPK/JNK
Pathway. To explore which of the signaling pathways are
required for ABR-induced upregulation of the PHB gene,
several speciﬁc chemical inhibitors were used. The eﬀect
of these inhibitors was examined using an ELISA-based
detection system (Figure 2(a)). Jurkat T cells were pretreated
with PD98059 (PD, MEK inhibitor; 20μM), SB203580 (SB,
p38 MAPK inhibitor; 20μM), or SP600125 (SP, JNK/SAPK
inhibitor;30μM)for1h,followedbytreatmentwithABRfor
the time indicated; total protein was used to determine PHB
expression. SP signiﬁcantly reduced the ABR-induced PHB
expression, whereas the 2 other kinase inhibitors PD and
SB rarely aﬀected on the upregulation of PHB (Figure 2(b)).
These results suggest the possible involvement of JNK/SAPK,
but not of ERK1/2 or p38 MAPK, in the regulation of PHB
expression in Jurkat T cells treated with ABR.
3.3. PHB Is Involved in ABR-Induced Cell Apoptosis. Since
ABR induced the expression of PHB, a tumor suppressor
gene that may induce cell apoptosis by arresting the cell
cycle at the G1/S phase, we focused on determining whether
PHBparticipatesintheapoptoticsignalingtriggeredbyABR.
Apoptosis induced by ABR (0.1 and 1nM) was investigated
using TUNEL method. As shown in Figure 3(a),g r o u p1
and 2, the maximal apoptotic response was achieved 18h
after treating cells with ABR (77.7% apoptosis after 1nM
ABR treatment versus 38.5% apoptosis after 0.1nM ABR
treatment;P<0.001).AlthoughthespeciﬁcPHBRNAinter-
ference(PHBsiRNA)did signiﬁcantlyenhancecellapoptosis
(PHB siRNA induces 22.8% apoptosis versus control siRNA
induces 7.4% apoptosis, P<0.001; Figure 3(a) groups 1
and 3), knockdown PHB reduced ABR-induced apoptosis
(PHB siRNA reduced 1nM ABR-induced apoptosis by 9.7%,
P<0.001, and PHB siRNA reduced 0.1nM ABR-induced
apoptosis by 16.6%, P<0.001; Figure 3(a) groups 2 and
4). Apoptosis-related genes including Bax, caspase-3, and
PARP were also examined. ABR signiﬁcantly induced the
expression of Bax (6.3-fold; P<0.001) as well as the
activation of caspase-3 and PARP in the Jurkat T cells
(Figure 3(b), lanes 1 and 2). However, the activation was
reduced when the PHB expression reduced (Figure 3(b),4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Abrin (ABR) upregulates prohibitin (PHB) expression through transcriptional regulation in Jurkat T cells. (a) ABR-induced
cytotoxic activity in a dose-dependent manner in Jurkat T cells after 24h treatment. The data are represented as mean ± SD from 3
independent experiments. (b) ABR (0.1–10nM) signiﬁcantly increased the expression of PHB after treatment for 9h. (c) ABR (1nM)-
induced upregulation of PHB in a time-dependent manner. (d) ABR-induced PHB upregulation requires de novo RNA synthesis.
lanes3and4).ThedatashowedthatPHBisinvolvedinABR-
triggered apoptosis.
3.4. Upregulation of Human Bax Expression through Translo-
cation of the PHB-p53 Complex from the Cytoplasm to
the Nucleus. The previously described results raised the
possibility that PHB may be involved in the apoptotic
processes triggered by ABR. On the other hand, increased
levels of PHB in the nucleus may interact with the tumor
suppressor protein p53 by which it exerts its apoptotic eﬀect.
Therefore, we attempted to determine whether there was an
interaction between PHB and p53. As shown in Figure 4(a),
PHB was translocated from the cytoplasm to the nucleus
after ABR treatment for 6h. Furthermore, a 1.3-, 1.4-, and
3.2-fold increase in p53 and a 1.1-, 1.3-, and 3.1-fold increase
in the interaction with PHB were observed when cells were
treated with ABR for 3, 6, and 9 h, respectively (Figure 4(b)).
These results indicated that ABR may induce a physical
interaction between PHB and p53 in the early stage of
ABR-induced cell apoptosis. Since Bax is known to be one
of the transcriptional regulation targets for PHB and p53,
a ChIP assay was performed by using speciﬁc primers to
amplify a potential p53-binding region in Bax. As shown in
Figure 4(c), p53 was recruited to the promoter regions of
Bax in a time-dependent manner. These results suggest that
ABR induces the formation of the PHB-p53 complex in the
nucleus, which enhances the transcriptional activity of p53
on Bax following apoptosis.
4. Discussion
Studieshaveshownthatsomeproteins,includingABR,ricin,
modeccin, diphtheria toxin, shiga toxin, and pseudomonas
toxin, are apoptosis inducers [32–34]. Although ABR has
beenclearlyidentiﬁedasaninducerofapoptoticcelldeathby
activating caspase-3 in several kinds of cancer cells [15, 35–
38], the mechanisms of its involvement in cell apoptosis
remain to be investigated. In this study, PHB is shown to
be upregulated in a dose-dependent manner during ABR
treatment and might play a potent role in ABR-triggered
apoptosis by enhancing the activity and expression of p53.
To the best of our knowledge, this is the ﬁrst study to explain
and demonstrate the role of PHB in ABR-induced apoptosis
in human leukemia cells. The potential clinical applications
of ABR may involve the enhancement of drug targeting as
well as a decrease in side eﬀects on noncancerous cells.
ABR is a RIP, which induces a shutdown of protein
synthesis in target cells [33, 39]. However, previous reports
also showed that the apoptosis-related protein Bax can be
upregulated by ABR [40, 41]. Our results also indicated
an overexpression of PHB and p53. One explanation isEvidence-Based Complementary and Alternative Medicine 5
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that cap-independent protein translation occurs in ABR-
triggered apoptosis [42]. Hence, although PHB was ﬁrst
deﬁned as a mitochondrial protein stabilizer [43], it was later
shown to have diverse functions in a variety of processes
including senescence, development, and tumor suppression
[44]. In addition, PHB enhances the transcriptional activity
of the tumor suppressor p53 via physical interaction [29,
45]. Our results are in agreement with earlier ﬁndings
that PHB can interact with and upregulate p53 function
during apoptosis [29]. It would, therefore, be interesting to
determine the involvement of other coactivators in the PHB-
p53 transcriptional activator complex upon ABR treatment.
Indeed, ABR may trigger cell apoptosis through its
protein synthesis inhibition, ribotoxic stress, mitochondrial
stress, PARP-induced NAD+ depletion, and ROS- and
nuclease-induced DNA damage [46]. In addition, others
and our previous works showed that ABR-induced apoptosis
seems to occur either concomitant with or before the
inhibition of protein synthesis [15, 46]. Although we have
not yet determined a correlation between the 3 diﬀerent
ABR-induced pathways (including depurination activity,
AOP-1 interaction, and prohibitin upregulation), both our
current study and previous results indicated that either
overexpressionofAOP-1orblockade ofPHBexpression may
signiﬁcantly reduce apoptosis (P<0.05 for each). ABR
upregulates the expression of, but does not interact with,
PHB. On the contrary, ABR interacts with AOP-1 without
upregulating it (data not shown). Although AOP-1 and PHB
are thought to share several conserved domains that are
expected to play similar roles in normal cells, the reason why
they display distinct functions upon ABR treatment is still
unclear;thiswouldbeaninterestingtopicforfurtherstudies.
In addition, it seems that the interaction of ABR with AOP-
1 is independent of depurination activity, and whether the
upregulation of PHB depends on depurination is open to
further study. Only an eﬃcient cellular transport system for
the toxicity-free mutant (ABR A chain E164Q) would be free
of intact protein contamination (e.g., the reassociation of the
A chain to the B chain).
Moreover, our results here show that early growth
response 1 (EGR1), a transcription factor that controls
the early growth response and facilitates tissue healing, is
signiﬁcantly upregulated by ABR in leukemia cells. This
result is in agreement with the response of lung epithelial
cells to ricin [47], which may well serve as one of the markers
of RIP-exerted toxicity. Ongoing studies are evaluating theEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: A model of abrin (ABR)-triggered apoptosis. ABR-induced apoptosis may occur through at least 3 pathways: ﬁrst, inhibition of
protein synthesis by its N-glycosidase activity; second, modulation of the function of mitochondria by speciﬁc interaction with antioxidant
protein-1 (AOP-1); and third, interference with the transcription regulated by prohibitin (PHB). Repression of prohibitin attenuates ABR-
triggered apoptosis via preventing the expression of BAX, cleaved-caspase 3, and cleaved-poly(ADP-ribose) polymerase (PARP). Once PHB
is upregulated by ABR through the JNK/SAPK signaling pathway, the expression of proapoptotic gene Bax is turned on through the nuclear
translocation and p53 interaction of PHB, by which activates the caspase cascade, and ﬁnally, apoptosis occurs.
potential oftheseABR-relatedgenesforclinicalintervention.
Nevertheless, as Abrus precatorius is labeled as a biological
weapon which may be fatal if eaten, development of a passive
vaccine or an antidote for ABR is necessary but under
investigation [48, 49]. More understanding of the molecular
mechanisms exerted by RIP family proteins may accelerate
their clinical applications.
In conclusion, we propose the model shown in Figure 5.
ABR exhibits biological functions involving at least 3 path-
ways: translational inhibition, mitochondrial dysfunction,
and transcriptional interfere through the upregulation of
PHB. Since the downregulation of PHB signiﬁcantly delays
apoptosis induced by ABR, PHB could be employed in
reducing the toxicity of immunotoxins and, hence, improve
the eﬃciency of cancer chemotherapy.
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